Intestinal calcium and phosphate transport machinery

The intestinal calcium and phosphate transport machinery is a complex system of channels, transporters, and regulatory proteins responsible for the absorption of essential minerals from the diet into the bloodstream [3, 7, 9]. Key components include the apical calcium channel TRPV6, the sodium-dependent phosphate cotransporter NaPi-IIb (SLC34A2), and the intracellular ferry protein Calbindin-D9k [3, 7, 11]. This machinery is primarily regulated by the Vitamin D Receptor (VDR) and the Calcium-Sensing Receptor (CaSR), which modulate the expression and activity of these transporters in response to systemic mineral levels [5, 12, 19]. Dysregulation of this system is central to the pathogenesis of chronic kidney disease-mineral and bone disorder (CKD-MBD), hyperphosphatemia, and osteoporosis [4, 15]. Therapeutic strategies targeting this machinery include Vitamin D analogs to enhance absorption and novel inhibitors like tenapanor or NaPi-IIb blockers to reduce phosphate uptake in renal failure patients [4, 18]. Additionally, the system involves paracellular pathways regulated by claudins, which are increasingly recognized as targets for managing mineral balance in patients with impaired renal function [9, 12]. The machinery also includes secondary transporters such as PiT-1 and PiT-2, which provide compensatory phosphate uptake when primary pathways are compromised [6, 15]. Overall, this integrated system ensures mineral homeostasis by coordinating intestinal uptake with renal excretion and bone turnover [2, 5].

Other names

Intestinal mineral transport systemIntestinal Ca/Pi absorption machineryIntestinal calcium and phosphate absorption systemIntestinal mineral absorption machinery

Drugs targeting this machinery act through several mechanisms: VDR agonists (e.g., calcitriol) increase the expression of calcium and phosphate transporters; CaSR agonists (e.g., cinacalcet) inhibit TRPV6-mediated calcium absorption; NaPi-IIb inhibitors (e.g., DS-2330) and pan-phosphate transporter inhibitors (e.g., EOS789) block active phosphate uptake; and NHE3 inhibitors (e.g., tenapanor) reduce paracellular phosphate absorption by modulating tight junction permeability [4, 15, 18, 19].